X

Trial Profile

A Phase IV Acceptability and Feasibility Trial of the Effects of Medication on Memory in Idiopathic Nondementing Parkinson's Disease.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pramipexole (Primary) ; Ropinirole (Primary)
Indications Parkinson's disease
Focus Pharmacodynamics
Acronyms MeMory PaD

Most Recent Events

14 Nov 2018 Status has been changed to discontinued.
23 Apr 2015 Accrual to Date is 100% according to the United Kingdom Clinical Research Network record
04 Sep 2014 Accrual to Date is 44% according to the United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com